Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.

Gan HK, Millward M, Hua Y, Qi C, Sai Y, Su W, Wang J, Zhang L, Frigault MM, Morgan S, Yang L, Lickliter JD.

Clin Cancer Res. 2019 Aug 15;25(16):4924-4932. doi: 10.1158/1078-0432.CCR-18-1189. Epub 2019 Apr 5.

PMID:
30952639
2.

First-in-Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers.

Okour M, Gress A, Zhu X, Rieman D, Lickliter JD, Brigandi RA.

Clin Pharmacol Drug Dev. 2019 Nov;8(8):1088-1099. doi: 10.1002/cpdd.691. Epub 2019 Apr 5.

PMID:
30950565
3.

A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.

Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, Guttendorf R, Higgin M, Pribyl J, Mozzoni K, Safferstein H, Catalano SM.

Alzheimers Dement (N Y). 2019 Jan 23;5:20-26. doi: 10.1016/j.trci.2018.11.001. eCollection 2019.

4.

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.

Khoo JK, Montgomery AB, Otto KL, Surber M, Faggian J, Lickliter JD, Glaspole I.

J Aerosol Med Pulm Drug Deliv. 2019 Jan 30. doi: 10.1089/jamp.2018.1507. [Epub ahead of print]

PMID:
30698487
5.
6.

Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults.

Manoff SB, Sausser M, Falk Russell A, Martin J, Radley D, Hyatt D, Roberts CC, Lickliter J, Krishnarajah J, Bett A, Dubey S, Finn T, Coller BA.

Hum Vaccin Immunother. 2019;15(9):2195-2204. doi: 10.1080/21645515.2018.1546523. Epub 2019 Jun 3.

PMID:
30427741
7.

Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects.

Tang KY, Lickliter J, Huang ZH, Xian ZS, Chen HY, Huang C, Xiao C, Wang YP, Tan Y, Xu LF, Huang YL, Yan XQ.

Cell Mol Immunol. 2019 May;16(5):473-482. doi: 10.1038/s41423-018-0029-8. Epub 2018 Apr 18.

PMID:
29670279
8.

Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.

Turner AM, Stolk J, Bals R, Lickliter JD, Hamilton J, Christianson DR, Given BD, Burdon JG, Loomba R, Stoller JK, Teckman JH.

J Hepatol. 2018 Aug;69(2):378-384. doi: 10.1016/j.jhep.2018.03.012. Epub 2018 Mar 21.

PMID:
29572094
9.

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.

Dredge K, Brennan TV, Hammond E, Lickliter JD, Lin L, Bampton D, Handley P, Lankesheer F, Morrish G, Yang Y, Brown MP, Millward M.

Br J Cancer. 2018 Apr;118(8):1035-1041. doi: 10.1038/s41416-018-0006-0. Epub 2018 Mar 13.

10.

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.

Beran J, Lickliter JD, Schwarz TF, Johnson C, Chu L, Domachowske JB, Van Damme P, Withanage K, Fissette LA, David MP, Maleux K, Schmidt AC, Picciolato M, Dieussaert I.

J Infect Dis. 2018 Apr 23;217(10):1616-1625. doi: 10.1093/infdis/jiy065.

11.

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.

Nebot N, Arkenau HT, Infante JR, Chandler JC, Weickhardt A, Lickliter JD, Sarantopoulos J, Gordon MS, Mak G, St-Pierre A, Tang L, Mookerjee B, Carson SW, Hayes S, Grossmann KF.

Br J Clin Pharmacol. 2018 Apr;84(4):764-775. doi: 10.1111/bcp.13488. Epub 2018 Jan 23.

12.

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.

Kansagra KA, Parmar D, Jani RH, Srinivas NR, Lickliter J, Patel HV, Parikh DP, Heading H, Patel HB, Gupta RJ, Shah CY, Patel MR, Dholakia VN, Sukhadiya R, Jain MR, Parmar KV, Barot K.

Clin Pharmacokinet. 2018 Jan;57(1):87-102. doi: 10.1007/s40262-017-0551-3.

13.

Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.

Schluep T, Lickliter J, Hamilton J, Lewis DL, Lai CL, Lau JY, Locarnini SA, Gish RG, Given BD.

Clin Pharmacol Drug Dev. 2017 Jul;6(4):350-362. doi: 10.1002/cpdd.318. Epub 2016 Dec 12.

14.

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.

Whittle JR, Lickliter JD, Gan HK, Scott AM, Simes J, Solomon BJ, MacDiarmid JA, Brahmbhatt H, Rosenthal MA.

J Clin Neurosci. 2015 Dec;22(12):1889-94. doi: 10.1016/j.jocn.2015.06.005. Epub 2015 Aug 13.

PMID:
26279503
15.

Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine.

Stein DS, Jain JP, Kangas M, Lefèvre G, Machineni S, Griffin P, Lickliter J.

Antimicrob Agents Chemother. 2015;59(6):3493-500. doi: 10.1128/AAC.00340-15. Epub 2015 Apr 6.

16.

PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial.

Misra H, Lickliter J, Kazo F, Abuchowski A.

Artif Organs. 2014 Aug;38(8):702-7. doi: 10.1111/aor.12341. Epub 2014 Aug 12.

PMID:
25113835
17.

An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.

Lickliter JD, Taylor K, Szer J, Grigg A, Arthur C, Hughes TP, Durrant S, Filshie R, Irving I, Seldon M, Ellacott J, Boyd AW, D'Rozario J, Rooney K, Lynch K, Bradstock K; Australasian Leukaemia and Lymphoma Group.

Leuk Lymphoma. 2015 Mar;56(3):630-8. doi: 10.3109/10428194.2014.925547. Epub 2014 Aug 4.

PMID:
24844361
18.

EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW.

Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007.

19.

Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent.

Burge M, Francesconi AB, Kotasek D, Fida R, Smith G, Wilks A, Vasey PA, Lickliter JD.

Invest New Drugs. 2013 Feb;31(1):126-35. doi: 10.1007/s10637-012-9813-y. Epub 2012 Mar 27.

PMID:
22451157
20.

ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.

Day BW, Stringer BW, Spanevello MD, Charmsaz S, Jamieson PR, Ensbey KS, Carter JC, Cox JM, Ellis VJ, Brown CL, Walker DG, Inglis PL, Allan S, Reynolds BA, Lickliter JD, Boyd AW.

Neuro Oncol. 2011 Nov;13(11):1202-12. doi: 10.1093/neuonc/nor119. Epub 2011 Aug 16.

21.

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.

Lickliter JD, Francesconi AB, Smith G, Burge M, Coulthard A, Rose S, Griffin M, Milne R, McCarron J, Yeadon T, Wilks A, Cubitt A, Wyld DK, Vasey PA.

Br J Cancer. 2010 Aug 24;103(5):597-606. doi: 10.1038/sj.bjc.6605841.

22.

Detection of homocysteine and C-reactive protein in the saliva of healthy adults: comparison with blood levels.

Dillon MC, Opris DC, Kopanczyk R, Lickliter J, Cornwell HN, Bridges EG, Nazar AM, Bridges KG.

Biomark Insights. 2010 Jul 20;5:57-61.

23.

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme.

Francesconi AB, Dupre S, Matos M, Martin D, Hughes BG, Wyld DK, Lickliter JD.

J Clin Neurosci. 2010 Aug;17(8):970-4. doi: 10.1016/j.jocn.2009.12.009. Epub 2010 Jun 11.

PMID:
20541421
24.

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction.

Lickliter JD, Cox J, McCarron J, Martinez NR, Schmidt CW, Lin H, Nieda M, Nicol AJ.

Br J Cancer. 2007 Feb 26;96(4):600-8.

25.

HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death.

Lickliter JD, Wood NJ, Johnson L, McHugh G, Tan J, Wood F, Cox J, Wickham NW.

Leukemia. 2003 Nov;17(11):2074-80.

PMID:
12931228
26.

Characterization of the Epha1 receptor tyrosine kinase: expression in epithelial tissues.

Coulthard MG, Lickliter JD, Subanesan N, Chen K, Webb GC, Lowry AJ, Koblar S, Bottema CD, Boyd AW.

Growth Factors. 2001;18(4):303-17.

PMID:
11519828
27.

Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation.

Lickliter JD, McGlave PB, DeFor TE, Miller JS, Ramsay NK, Verfaillie CM, Burns LJ, Wagner JE, Eastlund T, Dusenbery K, Weisdorf DJ.

Bone Marrow Transplant. 2000 Oct;26(7):723-8.

28.

Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis.

Lickliter JD, Kratzke RA, Nguyen PL, Niehans GA, Miller JS.

Exp Hematol. 1999 Oct;27(10):1519-27.

PMID:
10517493
29.

Embryonic stem cells express multiple Eph-subfamily receptor tyrosine kinases.

Lickliter JD, Smith FM, Olsson JE, Mackwell KL, Boyd AW.

Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):145-50.

30.
31.

Supplemental Content

Loading ...
Support Center